Heart Failure

This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant  or a left ventricular assist device (LVAD).

Impella Improves Survival and Heart Recovery
News | Cardiovascular Clinical Studies
First Patient Enrolled in Abiomed’s RECOVER IV Randomized Controlled Trial of Impella as a Therapy for AMI Cardiogenic Shock

November 28, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announces the first patient in the world has been ...

Home November 28, 2023
Home
First Phase 3 study of TNX-103 in PH-HFpEF patients to start in 4Q 2023 (The LEVEL Study)
News | FDA
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

November 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

Home November 27, 2023
Home
The first clinical trial to challenge the routine implantation of a defibrillator in myocardial infarction survivors with heart failure has enrolled its first patient.
News | Cardiovascular Clinical Studies
Trial to Prevent Sudden Death After a Heart Attack Enrolls First Patient

November 22, 2023 — The first clinical trial to challenge the routine implantation of a defibrillator in myocardial ...

Home November 22, 2023
Home
New data from the ARIES trial show for the first time that an aspirin-free regimen can improve outcomes for people living with the heart pump by reducing hospitalizations without increasing the risk of blood clots
News | Heart Valve Technology
Late-breaking Data Show an Aspirin-free Medication Regimen Benefits People with Abbott’s HeartMate 3 Heart Pump

November 20, 2023 — Abbott announced new late-breaking data that show advanced heart failure patients living with its He ...

Home November 20, 2023
Home
BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart Failure II study protocol
News | FDA
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

November 17, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiova ...

Home November 17, 2023
Home
Findings will help scientists understand how microgravity impacts the ability of human heart cells to withstand the stresses of space travel
News | Heart Failure
Mount Sinai Bioengineers Send Cardiac Muscle Samples Into Space to Study Heart Cell Biology in Microgravity

November 16, 2023 — Mount Sinai’s Cardiovascular Research Institute is sending bioengineered human heart muscle cells ...

Home November 16, 2023
Home
In the trial of more than 400 adults with heart failure in Israel, the app predicted the need for hospitalization about three weeks in advance of a heart failure event
News | Heart Failure
AI-phone App Detected Worsening Heart Failure Based on Changes in Patients’ Voices

November 16, 2023 — A smartphone app using artificial intelligence technology to detect changes in the voice of a person ...

Home November 16, 2023
Home
Researchers at the University of Leicester have discovered the mechanism by which cholesterol in our diet is absorbed into our cells
News | Cardiovascular Clinical Studies
Ground-breaking Discovery Could Pave the Way for New Therapies to Prevent Cardiovascular Disease and Stroke

November 15, 2023 — Researchers at the University of Leicester have discovered the mechanism by which cholesterol in our ...

Home November 15, 2023
Home
Real-world evidence from the AHA Scientific Sessions 2023 demonstrated that Eko's AI doubles valvular heart disease detection sensitivity over traditional methods
News | Wearables
Multicenter Validation of the Novel Vivio System for Non-Invasive Estimation of Elevated Left Ventricular End Diastolic Pressure

November 15, 2023 — Ventric Health, a healthcare technology company and medical device provider focused on ...

Home November 15, 2023
Home
The award recognizes leaders who have made major contributions to the fields of cardiovascular and stroke science
News | Heart Failure
American Heart Association Honors Gladstone President Deepak Srivastava with Distinguished Scientist Award

November 14, 2023 — Deepak Srivastava, MD, president of Gladstone Institutes and a renowned cardiovascular researcher ...

Home November 14, 2023
Home
Real-world evidence from the AHA Scientific Sessions 2023 demonstrated that Eko's AI doubles valvular heart disease detection sensitivity over traditional methods
News | Artificial Intelligence
Breakthrough Clinical Data: Eko Health's AI Significantly Improves Heart Disease Detection in Primary Care

November 14, 2023 — Eko Health, Inc., a leader in AI technology for heart and lung disease detection, today unveiled new ...

Home November 14, 2023
Home
Ultromics, a leading health technology company at the forefront of detection of heart failure and its phenotypes, announces a significant development regarding the reimbursement code for its flagship product, EchoGo Heart Failure.
News | Heart Failure
CMS publishes final Clinical APC rule for Ultromics EchoGo Heart Failure

November 13, 2023 — Ultromics, a leading health technology company at the forefront of detection of heart failure and ...

Home November 13, 2023
Home
Zerlasiran showed very significant and durable reductions in lipoprotein(a) of up to 99% Lp(a) levels remained around 90% lower than baseline at study endpoint
News | Cardiovascular Clinical Studies
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

November 10, 2023 — Silence Therapeutics plc, an experienced and innovative biotechnology company committed to ...

Home November 10, 2023
Home
Experts from the Smidt Heart Institute at Cedars-Sinai will present on a variety of topics at AHA 2023. Photo by Cedars-Sinai.
News | Atrial Fibrillation
Cedars-Sinai Investigators to Unveil New Heart Research at AHA 2023

November 10, 2023 — Cardiologists, cardiothoracic surgeons and interventionalists from the Smidt Heart Institute at ...

Home November 10, 2023
Home
News | Artificial Heart
Total Artificial Heart Developer BiVACOR Mechanical Engineer Receives Sezai Innovation Award at ISMCS Annual Conference

November 10, 2023 — BiVACOR, a clinical-stage medical device company developing the Total Artificial Heart (TAH), has ...

Home November 10, 2023
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now